healthspan
(14)
The $10,000 Oil Change for Humans: How Circulate Sold Blood Cleaning Before Longevity Was Proven
Circulate turned a decades-old hospital procedure into a private-pay longevity service, raised $12 million and sold to Viome. Its smartest product may not be plasma exchange at all - it is the operating system that lets clinics offer a complicated treatment while the science catches up.
Longevity Science Left the Clinic. Lifespanning Put It in a Shopping Cart.
A Miami media company spent two decades inside biohacking's inner circle. Now it grades 1,000+ longevity products against a 72-point rubric - and only sells the ones that survive.
GlycanAge
GlycanAge is a UK-registered, Croatian-founded longevity biotech that measures biological age by analyzing glycans - sugar molecules attached to immune-system antibodies. Built on roughly two decades of glycobiology research led by Professor Gordan Lauc, the company turns a finger-prick blood sample into a report on how fast a person is aging at the molecular level, plus a specialist consultation to guide lifestyle changes. It sells directly to consumers and is expanding its glycan biomarkers into hospitals and preventive-care systems.
PranaX
PranaX is a Houston-based regenerative medicine biotechnology company developing stem cell-derived exosome products to counter aging, inflammation, and tissue damage. Built on exosome technology exclusively licensed from The University of Texas MD Anderson Cancer Center, PranaX operates an FDA-registered cGMP facility at the Levit Green life science campus and is bringing to market a physician-directed exosome wellness supplement (ExoWELL) and a personal exosome banking service (ExoSTORE). The company closed an oversubscribed $17M Series A in early 2026.
Human Longevity, Inc.
Human Longevity, Inc. is a San Diego- and South San Francisco-based genomics and precision-health company founded in 2013 by genome-sequencing pioneer J. Craig Venter, Peter Diamandis, and Robert Hariri. It pairs clinical-grade whole genome sequencing with whole-body MRI, hundreds of blood biomarkers, and AI analytics - delivered through its Health Nucleus platform - to detect cancer, cardiovascular disease, and other age-related conditions before symptoms appear. After a decade building one of the world's largest longitudinal genotype-phenotype datasets, the company in 2026 launched a $599 clinical-grade whole genome report and spun out Human Life Foundation Models, Inc. to build large-scale AI foundation models for longevity science.
InsideTracker
InsideTracker is a Cambridge, Massachusetts personalized health and wellness company (legally Segterra, Inc.) that turns your blood, DNA, and wearable data into a science-backed action plan. Founded in 2009 by MIT-trained scientist Dr. Gil Blander, the platform analyzes dozens of blood biomarkers, estimates your biological 'InnerAge,' and recommends specific foods, supplements, and lifestyle changes to optimize performance, healthspan, and longevity. It has become a favorite of athletes and quantified-self enthusiasts and integrates directly with Garmin, Fitbit, Oura, and Apple devices.
OneSkin
OneSkin is a San Francisco biotech and direct-to-consumer skincare company founded by four Brazilian women scientists who set out to slow skin aging at the molecular level. Its flagship OS-01 peptide - identified from a library of 900+ candidates using computational screening and tested on lab-grown human skin models - targets senescent 'zombie' cells that drive wrinkles, thinning and loss of firmness. The company sells topical 'supplements' for the face, eyes, body and sun protection, and frames skin not as a cosmetic surface but as the body's largest organ and a lever on overall healthspan.
Generation Lab
Generation Lab is a San Francisco longevity biotech building SystemAge, a diagnostic that measures how fast your body is actually aging rather than predicting a number. Using DNA methylation analysis of hundreds of biomarkers, it reports biological ages across roughly 19 organ systems from a blood sample, then hands clinicians an actionable plan to track whether interventions are moving the needle. Founded in 2023 by CEO Alina Rui Su, UC Berkeley aging researcher Dr. Irina Conboy, and operator Michael Suswal, the company raised an $11M seed in October 2025 led by Accel and works with 275+ clinics across roughly 18 countries.
Mitrix Bio
Mitrix Bio is a Bay Area biotech startup building bioreactor-grown mitochondria - the cell's power plants - packaged into vesicles it calls 'Mitlets' and delivered by injection. Founded by former SLAC accelerator manager Tom Benson, the company treats the slow decline of mitochondria as a root cause of aging and aims to manufacture autologous, young mitochondria at industrial scale so clinicians can regenerate organs, boost immunity and cognition, and extend healthy human lifespan toward 130 years.
Rejuvenation Technologies Inc.
Rejuvenation Technologies is a Stanford-spun biotech developing modified-mRNA therapeutics that temporarily switch on telomerase to lengthen telomeres and reverse cellular aging in specific tissues. Its lead programs target fibrotic and age-related diseases such as pulmonary fibrosis, chronic liver disease and bone-marrow failure, delivered by proprietary tissue-targeted lipid nanoparticles. Backed by Khosla Ventures and Y Combinator, the company holds 50+ patents and is advancing toward Phase I clinical readouts.
Tune Therapeutics
Tune Therapeutics is a genetic-medicine company building tools to turn genes up or down without cutting DNA. Its TEMPO epigenetic-editing platform tunes gene expression the way a sound engineer rides a fader - reversible, programmable, and precise. Spun out of Duke's Gersbach Lab, Tune raised over $175M in Series B financing in January 2025 and is running first-in-human trials of TUNE-401, an epigenetic silencer for chronic hepatitis B, with the larger ambition of editing the genome's software to extend human healthspan.
Bold
Bold is a Los Angeles-based digital healthy-aging company that delivers personalized, clinically validated exercise, nutrition, and virtual-care programs to older adults. Available at no cost to roughly 12 million Medicare members through partnerships with Medicare Advantage plans and provider groups, Bold treats movement as medicine: its programs have been shown to reduce falls by up to 46%, increase weekly physical activity by 182%, and earn 91% member satisfaction. Founded by Amanda Rees and Hari Arul, the company has raised $27 million from investors including Andreessen Horowitz, Khosla Ventures, and Rethink Impact.
Retro Biosciences
Retro Biosciences is a clinical-stage longevity biotech in Redwood City, California with a single, unsubtle goal: add ten healthy years to the human lifespan. Founded in 2018 and launched publicly in 2021 with $180 million from OpenAI CEO Sam Altman, the company attacks aging at the cellular level across three platforms - autophagy enhancement, cellular reprogramming, and plasma-inspired therapeutics. Its lead drug, RTR242, an autophagy-restoring small molecule aimed at Alzheimer's disease, entered a first-in-human Phase 1 trial in 2025. A 2026 raise valued Retro at $1.8 billion.
Hone Health
Hone Health is a New York-based telemedicine clinic built for preventive and longevity care. It pairs at-home and in-person testing of 40+ biomarkers with physician-guided treatment plans for hormone optimization, menopause, weight loss, sexual health, thyroid and more, delivered nationwide on a subscription model starting around $129/month. After raising a $33M Series A in January 2025 and acquiring in-home care company ivee, Hone has tested 300,000+ patients and treats roughly 55,000 active members.